182 related articles for article (PubMed ID: 22753591)
1. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.
Yoo JY; Haseley A; Bratasz A; Chiocca EA; Zhang J; Powell K; Kaur B
Mol Ther; 2012 Feb; 20(2):287-97. PubMed ID: 22031239
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Yoo JY; Hurwitz BS; Bolyard C; Yu JG; Zhang J; Selvendiran K; Rath KS; He S; Bailey Z; Eaves D; Cripe TP; Parris DS; Caligiuri MA; Yu J; Old M; Kaur B
Clin Cancer Res; 2014 Jul; 20(14):3787-98. PubMed ID: 24815720
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL
Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053
[TBL] [Abstract][Full Text] [Related]
8. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
[TBL] [Abstract][Full Text] [Related]
9. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
11. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
12. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
Currier MA; Eshun FK; Sholl A; Chernoguz A; Crawford K; Divanovic S; Boon L; Goins WF; Frischer JS; Collins MH; Leddon JL; Baird WH; Haseley A; Streby KA; Wang PY; Hendrickson BW; Brekken RA; Kaur B; Hildeman D; Cripe TP
Mol Ther; 2013 May; 21(5):1014-23. PubMed ID: 23481323
[TBL] [Abstract][Full Text] [Related]
13. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.
Zhang W; Fulci G; Wakimoto H; Cheema TA; Buhrman JS; Jeyaretna DS; Stemmer Rachamimov AO; Rabkin SD; Martuza RL
Neoplasia; 2013 Jun; 15(6):591-9. PubMed ID: 23730207
[TBL] [Abstract][Full Text] [Related]
14. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.
Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ
Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
16. ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma.
Yoo JY; Yu JG; Kaka A; Pan Q; Kumar P; Kumar B; Zhang J; Mazar A; Teknos TN; Kaur B; Old MO
Mol Ther Oncolytics; 2015; 2():15008. PubMed ID: 27119105
[TBL] [Abstract][Full Text] [Related]
17. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.
Eshun FK; Currier MA; Gillespie RA; Fitzpatrick JL; Baird WH; Cripe TP
Gene Ther; 2010 Jul; 17(7):922-9. PubMed ID: 20508601
[TBL] [Abstract][Full Text] [Related]
18. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
19. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
20. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]